Therapeutic Drug Monitoring of Quetiapine in Adolescents with Psychotic Disorders

Abstract

Intoduction: There are developmental and age-dependent differences in the pharmacokinetics and the pharmacodynamics of drugs in children and adolescents. Therefore, there is a need to carry out standardised studies to find out therapeutic ranges of plasma/serum concentrations in psychopharmacotherapy of children and adolescents. The aim of this prospective study was to examine the relationship between quetiapine serum concentration, treatment response, and side effects in a clinical setting to elucidate the age-specific therapeutic range of quetiapine in adolescents.

Methods: Over a period of two years, therapeutic drug monitoring (TDM) was routinely performed in 21 adolescents (mean age was 15.9±1.5 years, 57% male) with psychotic disorders according to the guidelines of the AGNP TDM expert group. The psychopathology was assessed by using the Clinical Global Impression Scale (CGI) and the Brief Psychiatric Rating Scale (BPRS). Side effects were assessed by using the Dose Record and Treatment Emergent Symptom Scale (DOTES). Trough quetiapine concentrations were determined under steady state conditions after multiple-dose regimes (median 600 mg/day; range 100-800 mg/day).

Results: There was a marked variability of the serum concentrations, ranging from 19-877 ng/ml. 40.8% of the determined values were below and 24.5% above the therapeutic range (70-170 ng/ml) recommended for adults. None of the patients had severe side effects. We found a weak correlation between dose and serum concentration of quetiapine and no relationship between serum concentration and treatment response.

Discussion: There are several limitations of this study, and our results should therefore be interpreted with caution. Notwithstanding, differences in the ontogenesis of pharmacokinetics and pharmacodynamics may be the reason for the difference in the relationship between blood concentrations and therapeutic response to psychopharmaca in children, adolescents and adults. Further studies using larger samples, baseline assessment of psychopathology, definition of the treatment interval and investigation of clinically relevant interactions with various comedications are warranted to improve the limitations of this pilot study.

References

• 1 Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia. A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.  Biol Psychiatry. 1997;  42 233-246
• 2 Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M. et al . The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.  Pharmacopsychiatry. 2004;  37 243-265
• 3 Bergemann N, Abu-Tair F, Kress KR, Aderjan R, Kopitz J. Therapeutic drug monitoring of quetiapine.  The World Journal of Biological Psychiatry. 6 177 , FC-004.01
• 4 DeVane LC, Nemeroff CB. Clinical pharmacokinetics of quetiapine.  Clin Pharmacol. 2001;  40 509-522
• 5 Dragicevic A, Sachse J, Härtter S, Hiemke C, Müller MJ. Serum concentrations of quetiapine and clinical effects.  Pharmacopsychiatry. 2005;  38 47-48
• 6 Gerlach M, Warnke A. Allgemeine Aspekte und Besonderheiten der Neuro-Psychopharmakologie im Kindes- und Jugendalter. In: Gerlach M, Warnke A, Wewetzer Ch, editors Neuro-Psychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. Wien New York: Springer 2004: 51-60
• 7 Gerlach M, Rothenhöfer S, Mehler-Wex C, Fegert JM, Schulz E, Wewetzer Ch. et al . Therapeutisches Drug-Monitoring in der Kinder- und Jugend psychiatrie - Grundagen und praktische Empfehlungen.  Z Kinder-Jugendpsychiatr. 2006;  34 5-13
• 8 Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A. et al . Brain development during childhood and adolescence: a longitudinal MRI study.  Nat Neurosci. 1999;  2 861-863
• 9 Gilles M, Deuschle M, Kellner S, Shams M, Krumm B, Härtter S. et al . Paroxetine serum concentrations in depressed patients and response to treatment.  Pharmacopsychiatry. 2005;  38 118-121
• 10 Goldstein J, Arvanitis LA. ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of Phase II clinical trials.  CNS Drug Rev. 1995;  1 50-73
• 11 Guy W. ECDEU assessment manual. Rockville, National Institute of Mental Health 1976
• 12 Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J. et al . National kidney foundation's kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification.  Pediatrics. 2003;  111 1416-1421
• 13 Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Delopmental pharmacology - drug disposition, action, and therapy in infants and children.  N Engl J Med. 2003;  349 1157-1167
• 14 McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO. et al . Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumerate: an open-label trial in adolescents with psychotic disorders.  J Clin Psychiatry. 2000;  61 252-260
• 15 Mehler-Wex C, Martin M, Wewetzer Ch. Schizophrenie, schizotype und wahnhafte Störungen. In: Gerlach M, Warnke A, Wewetzer Ch, editors. Neuro-Psychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. Wien New York: Springer 2004: 283-290
• 16 Morselli PL, Cuche H, Zarifian E. Pharmacokinetics of psychotropic drugs in the pediatric patient. In: Mendlewicz J, van Praag HM, editors Childhood Psychopharmacology: Current concepts. Advances in Biological Psychiatry. Basel: Karger 1978: 70-86
• 17 Morselli PL, Bianchetti G, Durand G, Le-Heuzey MF, Zarifian E, Dugas M. Haloperidol plasma level monitoring in pediatric patients.  Ther Drug Monit. 1979;  1 35-46
• 18 National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.  Am J Kidney Dis. 2002;  39 1-266
• 19 Overall JE, Gorham DR. The brief psychiatric rating scale.  Psychol Rep. 1962;  10 799-812
• 20 Remschmidt HE, Schulz E, Martin M, Warnke A, Trott GE. Childhood-onset schizophrenia: A history of the concept and recent studies.  Schizophrenia Bull. 1994;  20 727-745
• 21 Remschmidt H, Theisen FM. Schizophrenia and related disorders in children and adolescents.  J Neural Transm. 2005;  (Suppl 69) 121-141
• 22 Retz W, Kornhuber J, Riederer P. Neurotransmission and the ontogeny of human brain.  J Neural Transm. 1996;  103 403-419
• 23 Rothenhöfer S, Mehler-Wex C, Schupp U, Wewetzer Ch, Gerlach M. Therapeutic drug monitoring of quetiapine in child and adolescents.  Pharmacopsychiatry. 2005;  38 61-62
• 24 Sachse J, Köller J, Hartter S, Hiemke C. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography (HPLC) with column switching and spectrophotometric detection.  J Chromatogr B. 2006;  830 342-348
• 25 Schimmelmann B, Schulze-zur-Wiesch C, Mehler-Wex C, Koch E, Flechtner HH, Gierow B. et al . A prospective, open-label study of quetiapine in adolescents with schizophrenia spectrum disorders.  J Child Adol Psychopharmacol. , submitted
• 26 Seeman P, Bzowej NH, Guan H-C, Bergeron C, Becker LE, Reynolds GP. et al . Human brain dopamine receptors in children and aging adults.  Synapse. 1987;  1 399-404
• 27 Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.  Arch Gen Psychiatry. 1997;  54 549-557
• 28 Wittmann M, Haen E. TDM von Quetiapin. Abstrac Book of Therapeutisches Drug Monitoring von Psychopharmaka. Sölden, Austria 2006

Correspondence